New antihypertensive drugs
New blood pressure drugs, including aldosterone synthase inhibitors and zilebesiran.
Key point
Aldosterone-targeted therapies, including aldosterone-synthase inhibitors and spironolactone, provide clinically meaningful systolic blood pressure reductions in resistant hypertension without increasing serious adverse events.
From: Effect of fourth-line antihypertensive therapy on clinic systolic blood pressure in resistant hypertension: a systematic review and meta-analysis (Blood Press, 2026 Dec) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 8, 8, 11, 8, 12.
All papers from the last 12 months
145 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Effect of fourth-line antihypertensive therapy on clinic systolic blood pressure in resistant hypertension: a systematic review and meta-analysisBlood Press2026 DecPMID 42371950Meta-analysisSystematic review
- Aldosterone-mineralocorticoid receptor signaling and residual cardiorenal risk in type 2 diabetesActa Diabetol2026 Oct 14PMID 42873316Review
- Recent advances in hypertension genomics and RNA interference-based therapeutics: the key to future management?Expert Rev Cardiovasc Ther2026 Oct 8PMID 42837221Review
- Baxdrostat in Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-AnalysisCardiovasc Drugs Ther2026 Oct 6PMID 42837060Systematic review
- Comparative Efficacy of Treatments for Resistant or Uncontrolled Hypertension: A Network Meta-Analysis of Randomized TrialsJACC Adv2026 Oct 5PMID 42832922
- Resistant Hypertension: State of the Art ReviewClin J Am Soc Nephrol2026 Oct 2PMID 42826060
- Aldosterone synthase inhibitors: biological rationale, mechanism of action, and results of clinical trialsAm J Hypertens2026 Oct 1PMID 42847230Review
- Aldosterone synthase inhibitors may alter how primary care treats hypertensionAm J Hypertens2026 Oct 1PMID 42847228Review
- From low renin to the primary aldosteronism spectrum: aldosterone synthase inhibitors and the endocrine management of hypertensionAm J Hypertens2026 Oct 1PMID 42847227Review
- The hypertension specialist's perspective: aldosterone synthase inhibitors to fill the gap in difficult-to-control and resistant hypertensionAm J Hypertens2026 Oct 1PMID 42847226Review
More cardiology trends
All specialties →Factor XI inhibitors
A newer class of anticoagulants that target factor XI or XIa.
Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.
Colchicine in cardiovascular disease
Colchicine as an anti-inflammatory therapy in coronary and cardiovascular disease.
Key point: Low-dose colchicine has demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent.
Renal denervation
A catheter procedure targeting renal nerves to lower blood pressure.
Intravascular lithotripsy
Shockwaves delivered through a balloon catheter to crack calcium in arteries.
CETP inhibitors
Drugs that block cholesteryl ester transfer protein, studied for lowering LDL cholesterol.
Vutrisiran
Studies of vutrisiran, an RNA interference therapy for transthyretin amyloidosis.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
baxdrostat[tiab] OR lorundrostat[tiab] OR zilebesiran[tiab] OR aprocitentan[tiab] OR "aldosterone synthase inhibitor"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.